Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 2 of 912345...Last »

Kmart settles hard-fought whistleblower case

Kmart Corp. agreed to pay $35.3 million to the federal government and a number of states to settle a whistleblower lawsuit.

Read More »

U.S. judge tosses verdict against AbbVie

A judge overturned a $150 million verdict against AbbVie, the first resulting from lawsuits claiming the company fraudulently misrepresented the risks of AndroGel.

Read More »

Ocular Therapeutix gets subpoena from SEC over eye pain drug

Ocular Therapeutix Inc. said the U.S. Securities and Exchange Commission (SEC) issued a subpoena seeking information about the company’s eye-pain drug Dextenza.

Read More »

Novartis drug Tasigna is approved by FDA as first CML therapy with Treatment-free Remission data in its label

Novartis announced that the FDA approved the inclusion of Treatment-free Remission data in the Tasigna (nilotinib) U. S. product label.

Read More »

Valeant says Bausch & Lomb’s over-the-counter eye drop gets FDA nod

Canadian drugmaker Valeant Pharmaceuticals International Inc. said the U.S. Food and Drug Administration approved Lumify drop to treat eye redness.

Read More »

Celgene’s Follicular Lymphoma Regimen Fails Phase III

Shares of Celgene plunged after the company announced Revlimid combined with Biogen’s Rituxan failed in a late-stage study of previously untreated patients with follicular lymphoma.

Read More »

FDA Rejects Agile’s Contraceptive Patch Twirla

Shares of Agile Therapeutics plunged more than 62 percent in early trading after the company announced that the U.S. FDA rejected its low-dose hormonal contraceptive patch called Twirla.

Read More »

U.S. FDA plans to let device makers report malfunctions less frequently

The U.S. Food and Drug Administration said it plans to let medical device makers report less serious malfunctions of some devices on a quarterly basis to cut down on repeated reviews of common problems.

Read More »

Combo therapy for melanoma gets priority review

The U.S. FDA granted priority review for Novartis’ Tafinlar in combination with Mekinist for treating some patients with advanced melanoma.

Read More »

Roche to buy U.S. cancer drugmaker Ignyta

Roche will buy U.S. cancer drugmaker Ignyta Inc. for $1.7 billion to broaden the Swiss drugmaker’s oncology portfolio globally.

Read More »

California court says Novartis can be sued over generic drug injuries

California’s top court opened the door for consumers to sue Novartis AG and other makers of brand-name pharmaceutical products over injuries blamed on generic versions of the drugs manufactured by other companies.

Read More »

FDA approves La Jolla’s low blood pressure drug

La Jolla Pharmaceutical said the U.S. Food and Drug Administration approved its drug Giapreza to treat dangerously low blood pressure.

Read More »

Janssen Enters Worldwide Collaboration and License Agreement with Chinese Company Legend Biotech to Develop Investigational CAR-T Anti-Cancer Therapy

Janssen Biotech Inc. entered into a worldwide collaboration and license agreement with Legend Biotech USA Inc. and Legend Biotech Ireland Limited to develop, manufacture and commercialize a chimeric antigen receptor (CAR) T-cell drug candidate, LCAR-B38M, which specifically targets the B-cell maturation antigen.

Read More »

First-in-Human Trial of New Immunotherapy Approach Shows Efficacy in Antibiotic Resistance

SAB Therapeutics announced its first-in-human trial of new immunotherapy approach has shown efficacy in antibiotic-resistant bacteria based on a recent paper published online in Clinical Infectious Diseases.

Read More »

FDA Grants Breakthrough Therapy Designation for Avelumab in Combination with Inlyta in Advanced Renal Cell Carcinoma

Merck KGaA and Pfizer Inc. announced that the U.S. FDA granted Breakthrough Therapy Designation for avelumab in combination with Inlyta (axitinib) treatment-naïve patients with advanced renal cell carcinoma.

Read More »

FDA Approves New Diabetes Drug From Merck, Pfizer

The U.S. FDA approved Merck’s and Pfizer’s Steglatro (ertugliflozin), a sodium-glucose co-transporter 2 (SGLT2)- inhibitor, which will square off against established drugs in the market.

Read More »

U.S. life expectancy fell in 2016 as opioid overdoses surged: CDC

Life expectancy in the United States dipped in 2016 as the number of deaths due to opioid drug overdoses surged and total drug overdose deaths rose 21 percent to 63,600, the U.S. Centers for Disease Control and Prevention said.

Read More »

Five Keys for How You Can Make Marketing All About the Patient

There is a fundamental disconnect between companies and consumers: Healthcare brands often fail to address patients’ emotional journeys.

Read More »

Roche scores cancer drug approvals in Europe, U.S.

Swiss drugmaker Roche won approvals for two cancer drugs in Europe and the United States, shoring up its position in new medicines as it braces for falling sales of older products.

Read More »

FDA to fast track cell therapy for heart failure

The FDA will fast track the review of Australian drug developer Mesoblast Ltd.’s cell therapy treatment for heart failure patients under a new designation rolled out in December 2016.

Read More »

Page 2 of 912345...Last »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!


Ad Right Bottom